Global Intellectual Property Specialists

Strategic global thinking for the pharmaceutical and biopharmaceutical industries

READ MORE

Our Capabilities

We use our global experience to support life sciences clients from early R&D to commercial launch, and beyond.

READ MORE

Explore our BioBlast®

View our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. 

READ MORE

Our People

Our lawyers and attorneys have science backgrounds, were trained at top tier firms, and most have experience in-house at multinational giants.

 

READ MORE

Award-winning IP services

Ranked internationally and domestically, our pharmaceutical, biopharmaceutical and life sciences focussed lawyers and attorneys are recognised as being among the best IP practitioners in the world.

Read More
PreviousNext
12345

PEARCE IP

Our Capabilities

Pearce IP is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys, to the pharmaceutical, biopharmaceutical and life sciences industries.

With staff based in Australia and New Zealand, we coordinate and execute local and multi-jurisdictional IP litigation strategies, provide IP/legal support for regional and global business development activities and licensing deals, and prosecute patent and trade mark applications around the world.

Patent: Legal and Attorney Services

Trade Mark: Legal and Attorney Services

Commercial IP Services

Regulatory Affairs Services

View our Capabilities

Since its establishment in 2017 boutique Pearce IP has dominated in the area of pharmaceutical patents. Thanks to its deep bench of talented professionals, any life sciences brief is dispatched with alacrity and poise.

IAM Patent 1000, 2024

IP SPECIALIST LAWYERS – PATENT ATTORNEYS – TRADE MARK ATTORNEYS

Our Leaders

Julie Ballance

Executive, Patent Attorney and Trade Mark Practitioner (AU, NZ), Lawyer (NZ) & Notary (NZ)

Sally Paterson

Executive, Patent & Trade Mark Attorney (AU, NZ), Lawyer (NZ)

Helen Macpherson

Executive, Lawyer (Head of Litigation - Australia)

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Adele Chadwick

Executive, Deputy CEO & Head of Talent

Paul Johns

Executive, Lawyer (Head of Litigation - New Zealand)

Kimberley Evans

Executive, Lawyer & Trade Mark Attorney (Head of Trade Marks)

Chris Coates (Maj Ret)

Executive, Finance

Julie Ballance

Executive, Patent Attorney and Trade Mark Practitioner (AU, NZ), Lawyer (NZ) & Notary (NZ)

Sally Paterson

Executive, Patent & Trade Mark Attorney (AU, NZ), Lawyer (NZ)

Helen Macpherson

Executive, Lawyer (Head of Litigation - Australia)

Naomi Pearce

CEO, Executive Lawyer (AU, NZ), Patent & Trade Mark Attorney (AU, NZ)

Adele Chadwick

Executive, Deputy CEO & Head of Talent

Paul Johns

Executive, Lawyer (Head of Litigation - New Zealand)

PEARCE IP BLOG

Read our latest updates & insights

Read all News Stories
Explore our BioBlast®

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

daratumumab | Darzalex® | J&J

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

dupilumab | Dupixent® | Sanofi-Aventis

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

faricimab | Vabysmo® | Roche

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

guselkumab | Tremfya® | Janssen

infliximab | Remicade® | Johnson & Johnson

ixekizumab | Taltz® | Eli Lilly

lecanemab | Leqembi® | Eisai/Biogen

liraglutide | Victoza® /Saxenda® | Novo Nordisk

natalizumab | Tysabri® | Biogen/Elan

nivolumab | Opdivo® | BMS

olaparib | Lynparza® | AstraZeneca/Merck

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

regdanvimab | Regkirona® | Celltrion

risankizumab | Skyrizi® | AbbVie

rituximab | Rituxan®/MabThera® | Genentech/Biogen

secukinumab | Cosentyx® | Novartis

semaglutide | Wegovy®/Ozempic® | Novo Nordisk

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson/Janssen

vedolizumab | Entyvio® | Takeda

View latest BioBlast® updates

See all Bioblast Updates

OUR VISION

By 2027, be the premier life sciences IP practice in
Australia and New Zealand.

Contact Our Team

AWARD WINNING IP SPECIALISTS LAWYERS - PATENT ATTORNEYS - TRADE MARK ATTORNEYS

Awards